NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Steroid-reducing Effects of Crisaborole

NCT03832010

CompletedPhase 4

Sponsor: Johns Hopkins University

Conditions: Atopic Dermatitis, Eczema

Interventions: Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor

Countries: United States

Atopic dermatitis, or eczema, is a chronic skin condition affecting many children. Crisaborole is a non-steroid topical medication which is FDA approved for children aged 2 and older for eczema. This research study seeks to investigate whether crisaborole reduces topical steroid use in children with atopic dermatitis.

Eligibility overview

Sex: ALL

Age: 2 Years to 17 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria:

* Children aged 2 or older (\<18).
* Diagnosed with atopic dermatitis.
* At baseline, AD is mild to moderate (score of 2 \[mild\] to 3 \[moderate\]) on the Investigator's Global Assessment scale (IGA; scores range 0-4, higher indicates greater severity).

Exclusion criteria:

* Known allergy to a constituent of the studied products (crisaborole, vehicle, Aquaphor, topical steroids \[hydrocortisone 2.5% ointment and triamcinolone acetonide 0.1% ointment\]).
* At baseline, AD is severe (score of 4 \[severe\] on the IGA scale).
* Medical problems which interfere with completion of protocols in this study.
* Pregnant or lactating females. (Females who have experienced menarche will be required to take a urine pregnancy test.)
* Participant is enrolled in another research study.
* Participant or participant's guardian(s) are unable to follow instructions as required in this study.

Locations (1)

Baltimore, Maryland, United States